No Data
Jiangsu Lianhuan Pharmaceutical (600513.SH): Supervisor Wang Chunyuan shareholding 1500 shares.
On November 11, Gelonhui announced that jiangsu lianhuan pharmaceutical (600513.SH) received a notification from the company supervisor, Mr. Wang Chunyuan, who, based on his recognition of the company's long-term investment value, increased his shareholding in the company by a total of 1,500 shares through the secondary market on November 8, 2024, using his own funds.
Improved Earnings Required Before Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) Stock's 28% Jump Looks Justified
Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s (SHSE:600513) Stock Is Going Strong: Is the Market Following Fundamentals?
Jiangsu Lianhuan Pharmaceutical (600513.SH): The shareholder structure of the controlling shareholder has been adjusted.
Gelonghui November 5th, Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company recently received a notification from the company's controlling shareholder, Lianhuan Group, stating that according to the "Lianhuan Group 38% State-owned Equity Transfer Agreement" signed between the Yangzhou State-owned Assets Supervision and Administration Commission and the Development and Reform Group, the Yangzhou State-owned Assets Supervision and Administration Commission transferred its 38% equity stake in Lianhuan Group to the Development and Reform Group without compensation, but the Development and Reform Group only has the dividend rights of the 38% equity stake in Lianhuan Group. The other shareholder rights are exercised and voted on by the Yangzhou State-owned Assets Supervision and Administration Commission. After the implementation of this equity transfer without compensation, the Development and Reform Group indirectly increased its shareholding in Jiangsu Lianhuan Pharmaceutical by 15.16 through
Jiangsu Lianhuan Pharmaceutical (600513.SH): Lidocaine and prilocaine aerosol received the drug clinical trial approval notice.
On November 5, Gelonhui announced that Jiangsu Lianhuan Pharmaceutical (600513.SH) recently received the Drug Clinical Trial Approval Notice of Lidocaine Prilocaine Aerosol issued by the National Medical Products Administration, and will soon conduct clinical trials. Lidocaine Prilocaine Aerosol is used to treat primary premature ejaculation in adult males. This product is not imported from the original research and there are no generic drugs available domestically yet.
Lianhuan Pharmaceutical's Piracetam Injection Passes Consistency Evaluation
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its ProblemsNo Data
No Data
